The UK’s National Institute for Health and Care Excellence (NICE) has sent a request to Eli Lilly asking for more data regarding Mounjaro (tirzepatide) before it will cover it for NHS patients. The decision comes based on data comparing the drug’s efficacy to Novo Nordisk’s rival drug Ozempic and standard insulin therapy. While the data showed Mounjaro was more effective at weight loss and glucose control, NICE needs more information before making a coverage decision.
Two recent value-assessment analyses found that many of the highest priced drugs in the US do not deliver enough beneficial effects to justify their list price. The first analysis came from the Institute for Clinical and Economic Review (ICER), which showed that the newly approved Alzheimer’s drug lecanemab was almost 20% higher than the maximum justified cost based on potential therapeutic benefits. The second analysis was published recently in JAMA examined Medicare spending on the top-selling prescription name brand drugs.
Linda Goler Blount, MPH, has been elected to join the governance board of the Institute for Clinical and Economic Review. Blount has worked in health policy and is currently the president of the Black Women’s Health Imperative. She has built a career on addressing health disparities, especially those disproportionately affecting Black women and girls.
The Institute for Clinical and Economic Review (ICER) released an update to its recently released value assessment of the Leqembi (lecanemab). ICER changed its price recommendation for Eisei’s new Alzheimer’s treatment to a range of $8,900 to $21,500 per year. This price is higher than its initial assessment but still lower than the drug’s list price.
The Institute for Clinical and Economic Review (ICER) releases value assessment reports that determine cost-effectiveness ratios (CERs) for new and existing therapeutics. A newly published study in the Journal of Managed Care + Specialty Pharmacy, examines whether and how commercial insurance plans in the US incorporate these reports into their reimbursement decision-making process.
With the passage of the Inflation Reduction Act by the US, pharma and biotech companies have to reevaluate their pricing strategies. In a Cytel webinar taking place on September 8th, Anna Forsythe of Cytel and Dr. Edmund Pezalla of Bioconsult discuss how these reforms will influence the field and how real-world evidence and health economics and outcomes research (HEOR) based research can help companies prepare.
Regulatory Scientific and Health Solutions (R-S-S) is hosting a course entitled, “Economic Evaluation of Cancer Drugs.” The course is aimed towards professionals in health economics and outcomes research (HEOR), market access, and clinical oncology. Attendees will learn about the development, application, and interpretation of economic models for cancer drugs. The course takes place at the Hilton London Watford, Watford, UK on Monday 3rd October 2022. Register by 1st August 2022 for an early bird discount.